Novo Nordisk reported earnings, posting some chunky year-over-year growth and far outperforming its only real rival at the moment, Eli Lilly.
Our daily email brings you smart and engaging news and analysis on the biggest stories in business and finance. For free.
The Food and Drug Administration declared an end to the scarcity of Eli Lilly’s highly in-demand weight-loss and diabetes drugs on Thursday.
In the obesity drug industry, two players have really been throwing their weight around. There isn’t a third in sight.
Novo Nordisk’s share price fell over 8% on Wednesday after the company reported lower-than-expected sales of Wegovy.
The deal puts an end to Fubo’s ongoing lawsuit that sought to block Disney’s efforts to build Venu Sports with Fox and Warner Bros. Discovery.
Record earnings from Foxconn and some fresh tariff news highlight core themes likely to dominate headlines this year.
People who work on Wall Street face a more quotidian challenge starting this morning: getting there, thanks to New York’s congestion pricing.